Company news

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A (SSE:600867) news

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement…

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A (SSE:600867) news

Press releases & updates

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Satisfaction of Unlocking Conditions for the First Lock-up Period of the Initial Grant under the 2025 Employee Stock Ownership Plan and Expiration of the Lock-up Period

(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Pledge Release and Re-pledge of Shares Held by the Controlling Shareholder

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Allocation of Reserved Portion under Employee Stock Ownership Plan for R&D and Production System

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Termination of an R&D Project and Provision for Asset Impairment

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Pledge Release and Re-pledge of Shares Held by the Controlling Shareholder

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Results of Exercising the Preemptive Rights to Subscribe for the Convertible Corporate Bonds Issued to Unspecified Investors by Xiamen Amoytop Biotech Co., Ltd.

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Release of Pledge and Re-pledge of Controlling Shareholder's Shares

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on the U.S. Food and Drug Administration Approval for Marketing of Insulin Aspart Injection

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Release of Pledge and Re-pledge of Controlling Shareholder's Shares

Announcement on Resolutions of the 26th Meeting of the 11th Board of Directors

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Obtaining Overseas Drug Registration Certificates for Liraglutide Injection

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Convening the 2025 Annual and Q1 2026 Performance Briefing and Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Jilin

Announcement on Resolutions of the 25th Meeting of the 11th Board of Directors

ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update

Announcement on Implementation of Daily Related Transactions in 2025 and Estimated Daily Related Party Transactions in 2026

Announcement on Implementation Results of Repurchasing Shares through Call Auction and Share Changes

Announcement on Progress in Repurchasing Shares through Call Auction

Rectification Report on Decision on Administrative Supervision Measures from Jilin Office of China Securities Regulatory Commission

Announcement on Receiving Decision on Administrative Supervision Measures from Jilin Securities Regulatory Bureau

Announcement on Expected Increase in Performance for 2025

Announcement on Appointment of Senior Management Members

Announcement on Changing Signing Engagement Partner and Signatory Certified Public Accountant by Audit Institution

Announcement on Resolutions of the 1st Holders' Meeting for Employee Stock Ownership Plan in R&D and Production System

Announcement on the Completion of Non-Trade Stock Transfer under the Employee Stock Ownership Plan for R&D and Production System Staff

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025

Announcement on Resolutions of the Employee Representative Meeting

Announcement on Obtaining Overseas Drug Registration Certificate for Insulin Aspart Injection

Announcement on Initially Repurchasing the Company's Shares through Call Auction

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Results of Share Increase by Controlling Shareholder

Announcement on Provision for Asset Impairment and Asset Write-off

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Subject to No Sales Restrictions Concerning Share Repurchase

Announcement on Canceling the Board of Supervisors, Amending the "Articles of Association" and Revising and Adding Some Governance Systems

ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D

Announcement on Obtaining of Overseas Marketing Authorization for Insulin Glargine Injection

Announcement on the Completion of Non-Trade Stock Transfer under the 2025 Employee Stock Ownership Plan

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Notice on Convening the 2nd Extraordinary General Meeting in 2025

Announcement on Resolutions of the 16th Meeting of the 11th Board of Directors

ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in People with T2D

ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update

Announcement on Expected Increase in Semi-annual Performance for 2025

Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report

Announcement on Resignation of Secretary of the Board of Directors

Announcement on the Completion of Share Transfer Registration for the Negotiated Transfer of Partial Shares of Xiamen Amoytop Biotech Co., Ltd.

Announcement on Completion of Stock Sales under the 2020 Employee Stock Ownership Plan

Indicative Announcement on Equity Change of Controlling Shareholder and Its Persons Acting in Concert Reaching 1%